Lixisenatide Meets Primary Efficacy Endpoint With Fewer Hypoglycaemias COPENHAGEN, Denmark, February 2, 2011 - Zealand Pharma A/S (NASDAQ OMX: ZEAL), a biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs, is pleased to announce that its partner, sanofi-aventis, today announced that the GetGoal-X Phase III study of lixisenatide, a once-daily GLP-1 receptor agonist licensed from Zealand Pharma, achieved its primary endpoint of non-inferiority in HbA1c reduction from baseline, compared with exenatide twice-daily.

New Application Programming Interface Enables Partners to Leverage blinkx's Web Video Index to Build New Functionality and Apps for the OTT environment

Alternative nodal pricing system can result in savings of at least euro 0.8 to euro 2.0 billion for system operation

Fitness First Australia Reduces Total Energy Consumption and Carbon Emission by 10 Percent, Wins Oracle’s ‘Enable the Eco-Enterprise’ Award